NCT05597761

Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC)

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 49 (actual)
• Sponsor: Oliver Cornely, MD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This multicenter, prospective, non-interventional study aims to evaluate data on humoral and cellular immune response generated within the COVID-19 vaccination standard in immunocompromised patients.

Detailed description

This study aims to analyze the immune response data generated within the procedures of the standard-of-care COVID-19 vaccination. for immunocompromised patients. Additional blood will be drawn from the patients at each visit defined within the vaccination standard by using the same vein puncture as used for blood drawings of routine blood samples. Study related blood samples will be used for evaluation of T and B cell response to COVID-19 vaccinations. For this study, no additional visits or invasive procedures will be performed in addition to the standard interventions.

Conditions

• COVID-19
• Adult
• Immunocompromised Patients

Timeline

• Start date: 2023-05-15
• Primary completion: 2025-09-30
• Completion: 2025-12-31
• First posted: 2022-10-28
• Last updated: 2025-05-14

Locations

3 sites across 1 country: Germany